AbCellera Q3 net loss widens to $57.1M; revenue rises to $9.0M

AbCellera Biologics Inc.

2025-Q3 EPS reported -$0.46 revenue$30,275,000

Net loss of $57.1M ($0.19/share) vs $51.1M ($0.17/share) in Q3 2024.
Total revenue $9.0M, up from $6.5M in Q3 2024.
Appointed Sarah Noonberg, M.D., Ph.D., as Chief Medical Officer.
Cumulative partner-initiated program starts with downstreams: 103; molecules in clinic: 18.
Total available liquidity $680M ($523M cash/securities + $159M non-dilutive funding).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.